|
November 17, 1997
APPOINTMENT NOTICE
Dr. Francine Gervais, Vice-President, Research & Development.
Dr. Louis R. Lamontagne, President & CEO of Neurochem Inc., is pleased to announce
the appointment of Dr. Francine Gervais to the position of Vice-President, Research and
Development.
Dr. Gervais brings broad research expertise to Neurochem. She comes to Neurochem with
15 years of experience on amyloid-related research as an Associate Professor with the
Department of Experimental Medicine at McGill University with joint appointments at the
Department of Microbiology & Immunology and the McGill Centre for the Studies on
Age and Aging. Dr. Gervais is a well-known and respected scientist for her work in the
area of mechanisms controlling amyloid deposition, Neurochem’s key technology.
Amyloid deposits are known to be associated with such diseases as Alzheimer’s
and adult-onset diabetes (Type II).
Neurochem is a Canadian bio-pharmaceutical company working in concert with financial
and industry partners to synthesize, develop and market breakthrough human health
therapeutics. Its unique technology is based on small organic molecules that control
amyloid deposits related to Alzheimer’s disease and adult-onset diabetes (Type II).
Neurochem was founded in 1993 by PARTEQ Innovations, the technology transfer arm of
Queen’s University. Neurochem has a strong network of international development
and collaborative relationships with the University of Toronto, Oxford University, the
Ontario Cancer Institute and other leading research institutes.
|
